Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib and Trametinib with SRS for BRAF+ Melanoma Brain Metastases
NCT02974803Phase 2Terminated
- Sponsor
- Canadian Cancer Trials Group
- Start
- Feb 2018
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dabrafenib + trametinib and trametinib in melanoma and brain metastases, sponsored by Canadian Cancer Trials Group. Started Feb 2018; status: terminated.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
melanomabrain metastases
Beyond the preview
Go deeper on NCT02974803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02974803.